Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program (PETRUS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2012 by Gustave Roussy, Cancer Campus, Grand Paris
Sponsor:
Information provided by (Responsible Party):
Gustave Roussy, Cancer Campus, Grand Paris
ClinicalTrials.gov Identifier:
NCT01786031
First received: December 3, 2012
Last updated: February 6, 2013
Last verified: December 2012
  Purpose

Toward personalised treatment in early metastatic prostate cancer based on the assessment of biomarkers in cancer tissue samples and circulating tumour cells.


Condition Intervention
Metastatic Castration Resistant Prostate Cancer Patients
Other: metastasis biopsy

Study Type: Interventional
Study Design: Endpoint Classification: Bio-availability Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program

Resource links provided by NLM:


Further study details as provided by Gustave Roussy, Cancer Campus, Grand Paris:

Primary Outcome Measures:
  • Biomarker [ Time Frame: assessed at the end of recruitment, up to 2 years ] [ Designated as safety issue: No ]
    success to evaluate at least one molecular analysis in tumor tissues (prostate and/or metastatic site) AND in CTC


Estimated Enrollment: 120
Study Start Date: December 2012
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: experimental
metastasis biopsy
Other: metastasis biopsy

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Prostate Cancer patients
  • Castration Resistant
  • Prostatic tissue available
  • Metastasis which may be biopsied

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01786031

Contacts
Contact: Christophe Massard 33 1 42 11 43 38 christophe.massard@igr.fr

Locations
France
Institut Gustave Roussy Recruiting
Villejuif, Val de Marne, France, 94805
Contact: Christophe Massard    142114338 ext +33    christophe.massard@igr.fr   
Contact: Aurélie ABOU LOVERGNE    142116250 ext +33    aurelie.aboulovergne@igr.fr   
Principal Investigator: Christophe Massard         
Sponsors and Collaborators
Gustave Roussy, Cancer Campus, Grand Paris
  More Information

No publications provided

Responsible Party: Gustave Roussy, Cancer Campus, Grand Paris
ClinicalTrials.gov Identifier: NCT01786031     History of Changes
Other Study ID Numbers: 2012-A00668-35
Study First Received: December 3, 2012
Last Updated: February 6, 2013
Health Authority: France: Agence Nationale de Sécurité du Médicament et des produits de santé

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms

ClinicalTrials.gov processed this record on October 23, 2014